Figueiredo G, Yu L, Jorge L, Woronik V, Dias C
Diagnostics (Basel). 2025; 15(2).
PMID: 39857004
PMC: 11763650.
DOI: 10.3390/diagnostics15020120.
Marinaki S, Kompotiatis P, Michelakis I, Stangou M, Papagianni A, Koukoulaki M
PLoS One. 2024; 19(12):e0315124.
PMID: 39693288
PMC: 11654980.
DOI: 10.1371/journal.pone.0315124.
Zhang H, Wang M, Zhou Y, Bao S, Wang F, Li C
Mar Drugs. 2024; 22(10).
PMID: 39452878
PMC: 11509176.
DOI: 10.3390/md22100469.
Stamellou E, Nadal J, Hendry B, Mercer A, Bechtel-Walz W, Schiffer M
Clin Kidney J. 2024; 17(7):sfae131.
PMID: 38989280
PMC: 11234294.
DOI: 10.1093/ckj/sfae131.
Bhayana S, Dougherty J, Kamigaki Y, Agrawal S, Wijeratne S, Fitch J
iScience. 2024; 27(1):108631.
PMID: 38188512
PMC: 10770536.
DOI: 10.1016/j.isci.2023.108631.
Develop and Validate a Risk Score in Predicting Renal Failure in Focal Segmental Glomerulosclerosis.
Cai Y, Liu Y, Tong J, Jin Y, Liu J, Hao X
Kidney Dis (Basel). 2023; 9(4):285-297.
PMID: 37899999
PMC: 10601954.
DOI: 10.1159/000529773.
Current understanding of the molecular mechanisms of circulating permeability factor in focal segmental glomerulosclerosis.
Salfi G, Casiraghi F, Remuzzi G
Front Immunol. 2023; 14:1247606.
PMID: 37795085
PMC: 10546017.
DOI: 10.3389/fimmu.2023.1247606.
Efficacy of extracorporeal plasma therapy for adult native kidney patients with Primary FSGS: a Systematic review.
Miao J, Krisanapan P, Tangpanithandee S, Thongprayoon C, Mao M, Cheungpasitporn W
Ren Fail. 2023; 45(1):2176694.
PMID: 36762994
PMC: 9930861.
DOI: 10.1080/0886022X.2023.2176694.
A Rare Nephrotic Syndrome Related to Chronic Lymphocytic Leukemia: Focal Segmental Glomerulosclerosis.
Karakus V, Atas U, Uzuntas S, Dere Y, Meteoglu I
Cureus. 2022; 14(11):e31545.
PMID: 36540526
PMC: 9754732.
DOI: 10.7759/cureus.31545.
Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease.
Chebotareva N, Vinogradov A, Brzhozovskiy A, Kashirina D, Indeykina M, Bugrova A
Int J Mol Sci. 2022; 23(20).
PMID: 36293475
PMC: 9604469.
DOI: 10.3390/ijms232012607.
Rituximab May Have Positive Effect on Refractory Nephrotic Syndrome: A Meta-Analysis of Randomized Trials.
Lin J, Sun J
Comput Math Methods Med. 2022; 2022:3008597.
PMID: 35813445
PMC: 9262522.
DOI: 10.1155/2022/3008597.
Prediction model for the risk of ESKD in patients with primary FSGS.
Zhu Y, Xu W, Wan C, Chen Y, Zhang C
Int Urol Nephrol. 2022; 54(12):3211-3219.
PMID: 35776256
DOI: 10.1007/s11255-022-03254-w.
Urinary Protein and Peptide Markers in Chronic Kidney Disease.
Chebotareva N, Vinogradov A, Mcdonnell V, Zakharova N, Indeykina M, Moiseev S
Int J Mol Sci. 2021; 22(22).
PMID: 34830001
PMC: 8625140.
DOI: 10.3390/ijms222212123.
Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis.
Troost J, Trachtman H, Spino C, Kaskel F, Friedman A, Moxey-Mims M
Am J Kidney Dis. 2020; 77(2):216-225.
PMID: 32791086
PMC: 7854818.
DOI: 10.1053/j.ajkd.2020.04.014.
Interleukin-18 binding protein attenuates renal injury of adriamycin-induced mouse nephropathy.
Dong M, Zhao M, Cui M, Sun J, Meng X, Sun W
Int J Clin Exp Pathol. 2020; 12(8):3005-3012.
PMID: 31934138
PMC: 6949725.
Urinary myo-inositol is associated with the clinical outcome in focal segmental glomerulosclerosis.
An J, Hyeon J, Jung Y, Choi Y, Kim J, Yang S
Sci Rep. 2019; 9(1):14707.
PMID: 31605028
PMC: 6789025.
DOI: 10.1038/s41598-019-51276-9.
Cardiovascular disease risk among children with focal segmental glomerulosclerosis: a report from the chronic kidney disease in children study.
Sethna C, Ng D, Jiang S, Saland J, Warady B, Furth S
Pediatr Nephrol. 2019; 34(8):1403-1412.
PMID: 30903375
PMC: 6594397.
DOI: 10.1007/s00467-019-04229-3.
[Minimal change disease and focal segmental glomerulosclerosis].
Muller-Deile J, Schenk H, Schiffer M
Internist (Berl). 2019; 60(5):450-457.
PMID: 30887070
DOI: 10.1007/s00108-019-0590-y.
Calcineurin Inhibitors With Reduced-Dose Steroids as First-Line Therapy for Focal Segmental Glomerulosclerosis.
Chavez-Mendoza C, Nino-Cruz J, Correa-Rotter R, Uribe-Uribe N, Mejia-Vilet J
Kidney Int Rep. 2019; 4(1):40-47.
PMID: 30596167
PMC: 6308907.
DOI: 10.1016/j.ekir.2018.08.010.
Treatment of steroid-resistant nephrotic syndrome in the genomic era.
Bensimhon A, Williams A, Gbadegesin R
Pediatr Nephrol. 2018; 34(11):2279-2293.
PMID: 30280213
PMC: 6445770.
DOI: 10.1007/s00467-018-4093-1.